Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $42.5252W HIGH $68.64
Volume
7.76 M
Value Traded
632.33 M
Short % Float
2.25%
Days to Cover
3.0
+4.73%Week
-3.55%1 Month
-1.52%3 Month
+6.63%6 Month
-11.57%5 Year
+2,822.58%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
125.85 B
EPS (TTM)
4.54
P/E Ratio
13.56
Ent. Value
157.64 B
Total Shares
2.04 B
Float Shares
2.04 B
Insiders
0.32%
Institutions
85.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BMY Catalyst Timeline
Dated clinical, regulatory and corporate events for Bristol-Myers Squibb Company
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bristol-Myers Squibb Company
586Total events
44Upcoming
388Tier-1 (high impact)
2019 to 2031Coverage
Upcoming catalysts 2
Event history 50
▲Late-Breakerizalontamab brengitecanFiledPresentation
Late-breaking oral presentation of PANKU-Breast01 at ESMO 2026
HR+/HER2- breast cancersource ↗
◆Oral PresentationNivolumabApprovedPresentation
Phase 3 neoadjuvant/adjuvant nivolumab results in muscle-invasive bladder cancer at ESMO 2026
muscle-invasive bladder cancersource ↗
◆Poster PresentationPresentation
Poster on homozygous MTAP deletion in advanced solid tumors at ESMO 2026
advanced solid tumorssource ↗
▲Additional Datazolacabtagene autoleucelClinical Data
Secondary efficacy results: 60/60 DL2 patients remained off DMTs; NEDA in 6/7 haRMS
highly active relapsing multiple sclerosis and progressive forms of multiple sclerosissource ↗
▲Oral Presentationzolacabtagene autoleucelPresentation
Interim Breakfree-2 results in haRMS and PMS presented orally at MSToronto 2026
highly active relapsing multiple sclerosis and progressive forms of multiple sclerosissource ↗
●Safety Data Updatezolacabtagene autoleucelClinical Data
Interim safety data from Breakfree-2 MS cohorts: CRS in 42.4%, ICANS in 7.6%
highly active relapsing multiple sclerosis and progressive forms of multiple sclerosissource ↗
▲Oral Presentationizalontamab brengitecanFiledPresentation
Late-breaking oral presentation of PANKU-Breast01 at ESMO 2026
HR+/HER2- breast cancersource ↗
▲Topline Readoutizalontamab brengitecanFiledClinical Data
Positive interim Phase 3 PANKU-Breast01 results reported
HR+/HER2- breast cancersource ↗
▲Primary Endpoint Metizalontamab brengitecanFiledClinical Data
PANKU-Breast01 met primary PFS endpoint (HR 0.41, p<0.0001)
HR+/HER2- breast cancersource ↗
▲Publicationizalontamab brengitecanFiledPresentation
PANKU-Breast01 results published in The Lancet
HR+/HER2- breast cancersource ↗
▲Partnership / LicenseCorporate
BMS and Pathos announce multi-year strategic collaboration with three-year neuroscience exclusivity
Alzheimer's disease and other neurological conditionssource ↗
▼Equity OfferingCorporate
Pathos AI closes $237 million Series E financing led by Bristol Myers Squibb
▲Primary Endpoint MetRYZ101Clinical Data
ACTION-1 met primary endpoint with statistically significant and clinically meaningful PFS improvement
SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs)source ↗
▲Primary Endpoint MetAdmilparantClinical Data
ALOFT-IPF met primary endpoint of absolute change in FVC at Week 52 at 60 mg dose
idiopathic pulmonary fibrosis (IPF)source ↗
▲Topline ReadoutRYZ101Clinical Data
Positive topline results from planned interim analysis of Phase 3 ACTION-1
SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs)source ↗
▲Topline ReadoutAdmilparantClinical Data
Topline results from pivotal Phase 3 ALOFT-IPF trial of admilparant in IPF
idiopathic pulmonary fibrosis (IPF)source ↗
▲Safety Data UpdateAdmilparantClinical Data
Admilparant demonstrated favorable safety and tolerability profile across both doses in ALOFT-IPF
idiopathic pulmonary fibrosis (IPF)source ↗
▲Interim AnalysisRYZ101Trial
Positive topline results from planned interim analysis of Phase 3 ACTION-1
SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs)source ↗
▲Topline ReadoutIberdomideApprovedClinical Data
Positive topline results from Phase 3 EXCALIBER-RRMM study of ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd)
Relapsed and Refractory Multiple Myelomasource ↗
▲Primary Endpoint MetIberdomideApprovedClinical Data
ZDd demonstrated statistically significant improvement in progression-free survival (PFS) vs. DVd
Relapsed and Refractory Multiple Myelomasource ↗
▲Label ExpansionCamzyosApprovedFDA Decision
FDA approves expanded indication for CAMZYOS (mavacamten) for symptomatic oHCM in adults and pediatric patients
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
▲FDA ApprovalCamzyosApprovedFDA Decision
FDA approves expanded indication of CAMZYOS for oHCM in adults and pediatric patients
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
◆Oral PresentationIberdomideApprovedPresentation
First presentation of Phase 3 EXCALIBER-RRMM results for iberdomide plus daratumumab
relapsed or refractory multiple myelomasource ↗
▲Topline ReadoutIberdomideApprovedClinical Data
First presentation of Phase 3 EXCALIBER-RRMM results for ZENBEXUS (iberdomide) + daratumumab + dexamethasone
relapsed or refractory multiple myelomasource ↗
▲Primary Endpoint MetIberdomideApprovedClinical Data
Dual primary endpoint of MRD-negative CR rate met in EXCALIBER-RRMM
relapsed or refractory multiple myelomasource ↗
▲Late-BreakerIberdomideApprovedPresentation
Late-breaking oral presentation [Abstract #LBA12] at IMS 2026
relapsed or refractory multiple myelomasource ↗
▲PublicationIberdomideApprovedPresentation
Results simultaneously published in The Lancet Oncology
relapsed or refractory multiple myelomasource ↗
▲Full ResultsSotyktuApprovedClinical Data
Two-year POETYK PsA-2 OLE results presented at CCR-West
psoriatic arthritissource ↗
▲Long Term DataSotyktuApprovedClinical Data
Sotyktu two-year (Week 104) efficacy and safety data in PsA
active psoriatic arthritissource ↗
▲Oral PresentationSotyktuApprovedPresentation
Sotyktu two-year PsA data presented at CCR-West 2026
psoriatic arthritissource ↗
▲Primary Endpoint MetClinical Data
QUINTESSENTIAL met primary endpoint of ORR
quadruple-class exposed relapsed and refractory multiple myelomasource ↗
▲Secondary Endpoint DataClinical Data
Key secondary endpoint of CRR met
quadruple-class exposed relapsed and refractory multiple myelomasource ↗
▲Topline Readoutarlocabtagene autoleucelClinical Data
Positive topline results from registrational Phase 2 QUINTESSENTIAL trial of arlo-cel in quadruple-class exposed RRMM
quadruple-class exposed relapsed and refractory multiple myeloma (RRMM)source ↗
▲Primary Endpoint Metarlocabtagene autoleucelClinical Data
QUINTESSENTIAL met primary endpoint of overall response rate
quadruple-class exposed relapsed and refractory multiple myeloma (RRMM)source ↗
▲Secondary Endpoint Dataarlocabtagene autoleucelClinical Data
QUINTESSENTIAL met key secondary endpoints of complete response rate and ORR
quadruple-class exposed relapsed and refractory multiple myeloma (RRMM)source ↗
●Safety Data Updatearlocabtagene autoleucelClinical Data
Safety profile of arlo-cel consistent with expectations
quadruple-class exposed relapsed and refractory multiple myeloma (RRMM)source ↗
▲Oral PresentationCamzyosApprovedPresentation
Late-breaker presentation of EXPLORER-LTE data at ESC Congress 2026
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
▲Long Term DataCamzyosApprovedClinical Data
EXPLORER-LTE data up to five years show sustained efficacy and safety
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
▲Partnership / LicenseCorporate
Chai Discovery announces collaboration with Bristol Myers Squibb for AI-driven antibody discovery
▲FDA ApprovalZENBEXUSApprovedFDA Decision
FDA granted accelerated approval to ZENBEXUS (iberdomide) for multiple myeloma
multiple myelomasource ↗
▲Primary Endpoint MetZENBEXUSApprovedClinical Data
EXCALIBER-RRMM met primary efficacy endpoint of MRD-negative complete response rate
multiple myelomasource ↗
▲FDA ApprovalZENBEXUSApprovedFDA Decision
FDA grants accelerated approval to ZENBEXUS in combination with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
multiple myelomasource ↗
▲Primary Endpoint MetZENBEXUSApprovedClinical Data
MRD-negative CR primary endpoint met in EXCALIBER-RRMM
multiple myelomasource ↗
▲Accelerated ApprovalIberdomideApprovedFDA Decision
FDA accelerated approval of ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone
multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agentsource ↗
▲Manufacturing MilestoneCMC / Inspection
BMS selects Houston, Texas for new $2.3 billion manufacturing campus
▲Partnership / LicenseCorporate
Schrödinger announces strategic collaboration and software agreement with Bristol Myers Squibb to deploy Bunsen
▲Orphan Drug DesignationRYZ101Designation
FDA granted RYZ101 Orphan Drug Designation for GEP-NETs
GEP-NETssource ↗
▲FDA Filing AcceptedMezigdomideFiledRegulatory Filing
FDA accepts NDA for Mezigdomide in R/R multiple myeloma
Relapsed or Refractory Multiple Myelomasource ↗
▲Partnership / LicenseCeeNU®Corporate
Septa Pharmaceuticals adquiere CeeNU (Lomustina) de Bristol Myers Squibb, Canadá
tumores cerebrales, linfoma de Hodgkinsource ↗
Past FDA Catalysts and PDUFA Decisions
How BMY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-25 | Pumitamig (PD-L1 × VEGF-A bsAb) | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
92
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma(rank 8 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Eliquis | |||
| Opdivo | |||
| Orencia | |||
| Yervoy | |||
| Reblozyl | |||
| Pomalyst/Imnovid | |||
| Revlimid | |||
| Breyanzi | |||
| Camzyos | |||
| Opdualag | |||
| Opdivo Qvantig | |||
| Zeposia |
Top 12 of 17 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Iza-bren Small moleculeNCT07100080 | Non-Small Cell Lung Cancer | Phase 3 | RECRUITING | 1,350 | Nov 15, 2030 | ||||||
| Iza-bren Small moleculeNCT06926868 | Breast Neoplasms | Phase 2 | RECRUITING | 600 | May 15, 2030 | ||||||
| Iza-bren Small moleculeNCT07106762 | Urothelial Cancer | Phase 2 | RECRUITING | 470 | Nov 18, 2033 | ||||||
| Izalontamab brengitecan Monoclonal antibodyNCT06618287 | Lung Cancer | Phase 1 | RECRUITING | 416 | Feb 26, 2031 | ||||||
| Arlocabtagene autoleucel CAR-TNCT06615479 | Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | RECRUITING | 440 | Jun 22, 2032 | ||||||
| Arlocabtagene autoleucel CAR-TNCT06121843 | Multiple Myeloma | Phase 2 | RECRUITING | 417 | Aug 1, 2028 | ||||||
| Pumitamig Small moleculeNCT07361510 | Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | RECRUITING | 1,600 | Oct 14, 2031 | ||||||
| Pumitamig Small moleculeNCT07221149 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Phase 2 | RECRUITING | 690 | Sep 11, 2032 | ||||||
| Pumitamig Small moleculeNCT07221357 | Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2 | RECRUITING | 990 | Mar 11, 2034 | ||||||
| Pumitamig Small moleculeNCT07871214 | Early-Stage Non-Small Cell Lung Cancer | Phase 2 | NOT YET_RECRUITING | 80 | Mar 15, 2028 | ||||||
| Pumitamig Small moleculeNCT07680764 | Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | RECRUITING | 160 | Sep 15, 2030 | ||||||
| Pumitamig Small moleculeNCT07291076 | Hepatocellular Carcinoma (HCC) | Phase 1 | RECRUITING | 198 | Oct 14, 2031 | ||||||
| Pumitamig Small moleculeNCT07293351 | Advanced Renal Cell Carcinoma (RCC) | Phase 1 | RECRUITING | 474 | Nov 26, 2031 | ||||||
| BMS-986489 Monoclonal antibodyNCT06646276 | Extensive-Stage Small Cell Lung Cancer | Phase 3 | RECRUITING | 530 | Jul 14, 2031 | ||||||
| Mezigdomide Small moleculeNCT05552976 | Relapsed or Refractory Multiple Myeloma | Phase 3 | ACTIVE NOT_RECRUITING | 1,416 | Jul 25, 2029 | ||||||
| Mezigdomide Small moleculeNCT03989414 | Multiple Myeloma | Phase 1 | ACTIVE NOT_RECRUITING | 746 | Nov 30, 2026 | ||||||
| Xanomeline and trospium chloride Small moleculeNCT05980949 | Psychosis Associated With Alzheimer's Disease | Phase 3 | RECRUITING | 1,910 | Sep 7, 2027 | ||||||
| Xanomeline and trospium chloride Small moleculeNCT07284745 | Irritability Associated With Autism Spectrum Disorder | Phase 3 | NOT YET_RECRUITING | 352 | Aug 6, 2029 | ||||||
| Xanomeline and trospium chloride Small moleculeNCT06951711 | Bipolar Disorder Type I With Mania or Mania With Mixed Features | Phase 3 | RECRUITING | 274 | Nov 2, 2026 | ||||||
| Xanomeline and trospium chloride Small moleculeNCT06951698 | Bipolar-I Disorder With Mania or Mania With Mixed Features | Phase 3 | RECRUITING | 274 | Nov 1, 2026 | ||||||
| Xanomeline and trospium chloride Small moleculeNCT06929273 | Bipolar Disorder Type I With Mania | Phase 3 | RECRUITING | 450 | Jun 13, 2028 | ||||||
| Xanomeline/Trospium Chloride Small moleculeNCT07140913 | Mania | Phase 3 | RECRUITING | 424 | Jun 28, 2027 | ||||||
| Xanomeline and trospium chloride Small moleculeNCT06976216 | Alzheimer Disease | Phase 3 | RECRUITING | 2,553 | Feb 23, 2029 | ||||||
| Xanomeline/Trospium Chloride Small moleculeNCT07011745 | Alzheimer Disease | Phase 3 | RECRUITING | 852 | Nov 13, 2028 | ||||||
| Navlimetostat Small moleculeNCT07492680 | Solid Tumors | Phase 2 | RECRUITING | 260 | May 20, 2032 |
Clinical Trial Results
Readouts, endpoints and source filings for every BMY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| izalontamab brengitecan Breakthrough | EGFR-mutated non-small cell lung cancer | Phase 3 | 2026-10-26 | median progression free survival iza bren: 11.1 months; median progression free survival pbc: 5.7 months; hazard ratio: 0.40; confidence interval: 0.31-0.51; p value: <0.0001; confirmed objective response rate iza bren: 60.2%; confirmed objective response rate pbc: 34.5%; median duration of response iza bren: 10.4 months; median duration of response pbc: 5.7 monthsRead More | Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 StudyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gallman CariOfficer (EVP, General Counsel) | Option | 4,559 18,208 held | $0.00 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BMY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1 % (-9.1 %) | 53.30 M | 925.00 K |
BMY Institutional Ownership Trends
BMY Short Interest
Shares sold short, counted twice a month.
2.25%
Short % of Float
of tradable shares sold short
45.8M
Shares Sold Short
+9.2% vs prior count
3.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
15.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BMY ranks across every disease it competes in
Competitive Position is a premium feature
See how BMY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBMY News
BMY▲ +0.2%today
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
SystImmune and Bristol Myers Squibb announced positive results from the Phase 3 PANKU-Lung01 study of izalontamab brengitecan (Iza-bren) in patients with previously-treated EGFR-mutated non-small cell lung cancer. Iza-bren demonstrated a median progression-free survival of 11.1 months, significantly better than the 5.7 months for platinum-based chemotherapy. The drug showed a favorable safety profile with minimal adverse events.
Read more →BMY▲ +0.2%today
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
Bristol Myers Squibb presented interim results from the Phase 1 Breakfree-2 study of zolacabtagene autoleucel (BMS-986353) for multiple sclerosis at MSToronto 2026. The study showed promising efficacy, with all patients at dose level 2 remaining off disease-modifying therapies. However, there were safety concerns, including one fatal event and a Grade 4 adverse event.
Read more →BMY▲ +0.2%today
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
Pathos AI has announced strategic collaborations with Bristol Myers Squibb and Tempus AI to enhance AI-driven drug development for Alzheimer's and other neurological conditions. Tempus will create a comprehensive dataset from neurological patients, while BMS will leverage Pathos's AI platform to improve clinical trial designs. This partnership aims to accelerate insights into disease progression and therapy development.
Read more →BMY▲ +0.2%today
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
Tempus AI has entered a multi-year agreement with Bristol Myers Squibb to license oncology data through 2031. This collaboration enhances BMS's access to Tempus' Lens Platform, which utilizes AI for drug development. The partnership aims to accelerate drug discovery and improve patient outcomes in oncology.
Read more →BMY▲ +0.2%today
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
Pathos AI has raised $237 million in Series E financing, boosting its valuation to approximately $3 billion. The funds will enhance its AI platform, Foundry, and support the clinical development of its oncology pipeline, including the advancement of JSKN016. The company aims to improve drug development success rates through innovative AI-driven strategies.
Read more →BMY▲ +0.2%today
Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
Bristol Myers Squibb and SystImmune reported positive Phase 3 PANKU-Breast01 results for izalontamab brengitecan (iza-bren). The drug reduced the risk of disease progression or death by 59% versus chemotherapy in advanced HR+/HER2- breast cancer. Median progression-free survival reached 8.2 months compared to 4.0 months for the control arm. The data will be presented at ESMO 2026 and published in The Lancet.
Read more →BMYIHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials
The Institute for Healthcare Improvement and Bristol Myers Squibb launched a three-year initiative to enhance access to oncology clinical trials. The Cancer Collective Action Collaborative aims to address barriers faced by underrepresented populations, particularly in lung and breast cancer. The initiative will involve 24 teams working to improve patient engagement and trial participation.
Read more →BMYBristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Bristol Myers Squibb will present significant oncology data at the ESMO 2026 Congress, including late-breaking Phase 2 and Phase 3 studies for its investigational drugs, izalontamab brengitecan and pumitamig. The presentations will cover a range of solid tumors, showcasing the company's advancements in cancer treatment and its focus on improving patient outcomes.
Read more →BMYBristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Bristol Myers Squibb has announced positive topline results from the interim analysis of its Phase 3 ACTION-1 trial for RYZ101, a radiopharmaceutical therapy. This trial focuses on patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The results indicate a promising potential for RYZ101 in treating this patient population.
Read more →BMYBristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Bristol Myers Squibb has announced that its Phase 3 ALOFT-IPF trial evaluating Admilparant in adults with idiopathic pulmonary fibrosis has successfully met its primary endpoint. This achievement highlights the potential of Admilparant as a treatment option for this serious condition. The results may pave the way for further developments in the management of idiopathic pulmonary fibrosis.
Read more →BMYOn the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative
Bristol Myers Squibb (BMS) celebrated the 12th Global Patient Week in Saudi Arabia by collaborating with the Saudi Schizophrenia Association to launch the 'Small Wins' initiative. This program aims to support individuals living with schizophrenia through personalized toolkits that promote daily engagement and emotional well-being. BMS employees actively participated in assembling these kits, reinforcing the company's commitment to patient-centered care.
Read more →BMYBristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
Bristol Myers Squibb has announced that ZENBEXUSTM (iberdomide), in combination with Daratumumab and Dexamethasone, has demonstrated superior progression-free survival compared to standard care in patients with relapsed and refractory multiple myeloma. This finding comes from a Phase 3 clinical trial, highlighting the potential of this combination therapy to improve treatment outcomes for patients.
Read more →BMYDriving Community Health: Bristol Myers Squibb, Emirates Thalassemia Society and Dubai Science Park Host the 6th 'Help Save a Life' Blood Donation Drive
Bristol Myers Squibb, in collaboration with the Emirates Thalassemia Society and Dubai Science Park, hosted the sixth 'Help Save a Life' blood donation drive in Dubai. This initiative aims to support patients with chronic blood disorders by mobilizing community members to donate blood. The event highlights the importance of reliable blood supplies for patients' treatment and reinforces the commitment to patient care in the UAE.
Read more →BMYBristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Bristol Myers Squibb has expanded its Champions in Care initiative, now in its second year, to honor healthcare professionals and support medically underserved communities. The campaign introduces a $1 million grant program for nonprofit organizations, allowing healthcare professionals to nominate groups that address community healthcare gaps. Nominations are open until November 30, 2026.
Read more →BMYU.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
The U.S. FDA has approved an expanded indication for Bristol Myers Squibb's CAMZYOS (mavacamten), allowing its use in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in both adults and pediatric patients. This approval reflects the drug's efficacy and the company's commitment to addressing this serious condition. The expanded use is expected to enhance treatment options for patients suffering from oHCM.
Read more →BMYBristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb has announced the first presentation of results for ZENBEXUS™ (iberdomide) in combination with Daratumumab from the Phase 3 EXCALIBER-RRMM trial. This trial focuses on patients with relapsed or refractory multiple myeloma, showcasing the potential of this combination therapy. The announcement marks a significant step in the ongoing development of innovative treatments for this patient population.
Read more →BMYNew Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP
Bristol Myers Squibb (BMS) has joined the Rare Access Action Project (RAAP) to enhance efforts in addressing access challenges for rare disease patients. BMS's participation is expected to bring valuable insights and strengthen the coalition's mission to improve patient access to innovative treatments. The collaboration aims to foster solutions that benefit patients facing serious diseases.
Read more →About Bristol-Myers Squibb Company
HeadquartersROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543
BIOPHARMAWATCH ELITE PLUS
Trade the next BMY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime